Bifidobacterium breve HH079 and its products and applications

By providing the highly tolerant Bifidobacter brevis HH079, the problems of immunity and intestinal dysfunction caused by gastrointestinal diseases are solved, and the intestinal health is improved and immunity is improved, which is suitable for enhancing the body's immunity.

CN118853502BActive Publication Date: 2024-11-22BIOSTIME GUANGZHOU HEALTH PROD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411299552.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-18
Publication Date
2024-11-22
Estimated Expiration
2044-09-18

AI Technical Summary

Technical Problem

The prior art is difficult to effectively improve human immunity and improve intestinal function, especially the problems of immunity reduction and toxin accumulation caused by gastrointestinal diseases, and the traditional methods are slow to effect.

Method used

Provide a Bifidobacterium brevis HH079 and its products, which have good gastric acid and bile salt tolerance, can withstand extreme environments of the digestive tract, improve structural integrity of intestinal epithelial cells, regulate proinflammatory factors and anti-intestinal flora disorders The level of inflammation factor promotes the polarization of macrophages M2, thereby improving the body's immunity.

Benefits of technology

Bifidobacterium brevis HH079 can effectively resist the extreme environment of the digestive tract, improve intestinal health, and improve immunity. It is used to prepare products that enhance the body's immunity and has good application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118853502B_ABST
    Figure CN118853502B_ABST
Patent Text Reader

Abstract

The present invention provides a Bifidobacterium breve HH079 and its products and applications. The Bifidobacterium breve HH079 provided by the present invention was deposited in the Guangdong Provincial Microbial Culture Collection Center on December 29, 2023, with a deposit number of GDMCC No: 64216. The Bifidobacterium breve HH079 provided by the present invention has good tolerance to gastric acid and bile salts, and can effectively resist the extreme environment of the upstream digestive tract, thereby smoothly reaching the downstream digestive tract (such as the colon) and exerting a healthy function. Bifidobacterium breve HH079 can improve the structural integrity of intestinal epithelial cells, regulate the levels of pro-inflammatory and anti-inflammatory factors in the body after intestinal flora imbalance, promote macrophage M2 polarization, and regulate intestinal flora, thereby improving the body's immunity. The Bifidobacterium breve HH079 provided by the present invention provides a good application prospect for the preparation of products that enhance the body's immunity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms, and specifically relates to Bifidobacterium breve HH079 and products and applications thereof. Background Art

[0002] Immunity is the body's own defense mechanism. It is the body's ability to identify and eliminate any foreign bodies (viruses, bacteria, etc.) that invade from outside, deal with aging, damaged, dead, and degenerated cells, and identify and deal with mutant cells and virus-infected cells in the body. A body with low immunity is more susceptible to infection or cancer. Children's weak resistance can lead to physical and intellectual stunting, and are more likely to induce major diseases, and will cause existing health problems to recur. Therefore, modern people are paying more and more attention to improving their own immunity.

[0003] The stomach is the most important organ in the human digestive system. It is the place where the body exchanges substances with the outside world. The nutrients necessary for human life activities are absorbed by the stomach, and more than 90% of the toxins in the body are discharged from the intestines. There is a saying that "nine out of ten people have stomach problems". Chronic colitis, old stomach problems, peptic ulcers and other gastrointestinal diseases seriously endanger human health. If gastrointestinal diseases are not effectively treated for a long time or are not cured for a long time, they will cause gastrointestinal mucosal erosion, ulcers, perforation and even cancer. At the same time, as a common and high-incidence disease, gastrointestinal diseases not only make people suffer from body pain, but also accumulate toxins in the body, block the body's nutritional source, reduce the body's immunity, and cause serious complications. At present, the methods of enhancing immunity are mostly diet conditioning, strengthening exercise, zinc supplementation, etc., but the effects of these are relatively slow.

[0004] With the further development of the field of microbiology, more and more experiments have proved that probiotics can improve human immune health. The human intestine is a complex ecosystem, in which there are a large number of microorganisms, which together constitute the intestinal flora. These bacteria can participate in the physiological processes of material metabolism, nutrient absorption, immune regulation and inflammation in the human body and play an important role.

[0005] As a kind of active microorganisms that are beneficial to the host, probiotics play many important roles in maintaining human health. First of all, probiotics have the function of regulating the balance of intestinal flora. On the one hand, probiotics can inhibit the colonization and reproduction of harmful bacteria by competing for ecological niches and nutrients in the intestine. On the other hand, probiotics help to strengthen the tight connection between intestinal epithelial cells, reduce intestinal permeability, and prevent harmful substances and pathogens from invading the body. Secondly, probiotics can enhance immunity. Studies have shown that probiotics can activate immune cells such as macrophages and natural killer cells, and improve their ability to phagocytize and kill pathogens. By regulating the balance of helper T cells (Th1 / Th2), excessive inflammatory responses can be reduced and the occurrence of immune-related diseases can be prevented. Many clinical studies have found that individuals who take probiotics for a long time have relatively stable levels of immunoglobulins in their serum, indicating that the immune system is in a well-regulated state. Thirdly, probiotics can improve the health of the digestive system. Probiotics have a certain regulatory effect on diarrhea and constipation caused by infection, drugs or improper diet.

[0006] Research on the role of probiotics in the body's immunity has shown initial results. Currently, more probiotics need to be developed to enhance immunity and improve intestinal function. Summary of the invention

[0007] In order to solve the above problems, the present invention provides a Bifidobacterium breve HH079 and its products and applications. The Bifidobacterium breve HH079 provided by the present invention was deposited in the Guangdong Provincial Microbiological Culture Collection Center on December 29, 2023, with a deposit number of GDMCC No: 64216. The Bifidobacterium breve HH079 provided by the present invention has good tolerance to gastric acid and bile salts, and can effectively resist the extreme environment of the upstream digestive tract, thereby smoothly reaching the downstream digestive tract (such as the colon) and exerting a healthy function. Bifidobacterium breve HH079 can improve the structural integrity of intestinal epithelial cells, regulate the levels of pro-inflammatory and anti-inflammatory factors in the body after intestinal flora imbalance, promote macrophage M2 polarization, and regulate intestinal flora, thereby improving the body's immunity. The Bifidobacterium breve HH079 provided by the present invention provides a good application prospect for the preparation of products that enhance the body's immunity.

[0008] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0009] In one aspect, the present invention provides a Bifidobacterium breve ( Bifidobacterium breve ), the Bifidobacterium breve is Bifidobacterium breve HH079, and its preservation number is GDMCC No: 64216.

[0010] Specifically, the Bifidobacterium breve HH079 is classified and named Bifidobacterium breve, the deposit number is GDMCC No: 64216, and it was deposited in Guangdong Provincial Microbiological Culture Collection Center on December 29, 2023.

[0011] On the other hand, the present invention provides a culture of Bifidobacterium breve HH079, wherein the preservation number of the Bifidobacterium breve HH079 is GDMCC No: 64216.

[0012] Specifically, the culture includes live bacteria, inactivated bacteria, broken bacteria, secretions and / or metabolites of Bifidobacterium breve HH079.

[0013] Preferably, the metabolites include one or more of enzymes, exopolysaccharides or bacteriocins.

[0014] Preferably, the metabolites contain immunogenic components.

[0015] Specifically, the method for preparing the culture comprises: inoculating Bifidobacterium breve HH079 into a culture medium.

[0016] Preferably, the culture medium comprises a solid culture medium or a liquid culture medium.

[0017] Preferably, the culture medium can provide nutrients to Bifidobacterium breve HH079.

[0018] Further preferably, the nutritional ingredients include one or more of protein, carbohydrate, fat, probiotics, enzymes, vitamins, minerals, amino acids, and milk substitutes.

[0019] In yet another aspect, the present invention provides a probiotic composition, comprising the above-mentioned Bifidobacterium breve or culture thereof.

[0020] Specifically, the probiotic composition also includes nutrients that are acceptable to food science.

[0021] Preferably, the food-friendly nutrient includes one or more of dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0022] In another aspect, the present invention provides the use of the above-mentioned Bifidobacterium breve or culture in the preparation of a product for enhancing immunity of an organism.

[0023] Specifically, the product contains 1×10 6 -1×10 12 CFU / dose of Bifidobacterium breve HH079.

[0024] Preferably, the product contains 1×10 8 -1×10 12CFU / dose of Bifidobacterium breve HH079.

[0025] More preferably, the product contains 1×10 9 CFU / dose of Bifidobacterium breve HH079.

[0026] Preferably, the CFU / dose includes but is not limited to CFU / g, CFU / mL or CFU / portion.

[0027] Specifically, the products include health products or medicines.

[0028] Preferably, the health care product enhances the body's immunity by enhancing gastrointestinal immunity, regulating intestinal flora, moistening the intestines and facilitating bowel movements, assisting in protecting the gastrointestinal mucosa or aiding digestion.

[0029] Preferably, the Bifidobacterium breve HH079 in the health product enhances the body's immunity by improving the structural integrity of intestinal epithelial cells, maintaining the intestinal barrier function, regulating the intestinal flora, regulating the levels of pro-inflammatory and anti-inflammatory factors in the body and / or promoting macrophage M2 polarization.

[0030] In another aspect, the present invention provides a health product comprising the above-mentioned Bifidobacterium breve or its culture.

[0031] Specifically, the health care product also includes nutritional additives that are nutritionally acceptable.

[0032] Preferably, the nutritional additives include one or more of dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0033] Specifically, the dosage forms of the health care products include tablets, capsules, soft capsules, granules, pills, gel candies, powders, oral liquids or drops.

[0034] In yet another aspect, the present invention provides a food comprising the above-mentioned Bifidobacterium breve or culture thereof.

[0035] Specifically, the food also includes nutritional additives that are nutritionally acceptable.

[0036] Preferably, the nutritional additives include one or more of dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0037] Specifically, the dosage form of the food includes a liquid dosage form, a solid dosage form or a semi-solid dosage form.

[0038] Preferably, the food includes candy flakes, soy milk, yogurt, canned food, biscuits, chocolate, cakes, cream, cheese, sour cream, milk powder, formula milk powder, ice cream, jam, puree, candied fruit, preserved fruit, bread, egg rolls, protein drinks, solid drinks, lactic acid bacteria drinks, plant protein drinks, carbonated drinks, coffee or puffed food.

[0039] Specifically, the food includes human food or animal food.

[0040] In yet another aspect, the present invention provides a medicament comprising the above-mentioned Bifidobacterium breve or culture thereof.

[0041] Specifically, the medicine further includes one or more physiologically acceptable auxiliary materials or pharmaceutically acceptable excipients.

[0042] Preferably, the physiologically acceptable excipients include, but are not limited to, erythritol, D-mannitol, fumaric acid, glycerol, pectin, potassium alginate, sodium alginate, talc, sodium pyrophosphate, polydextrose, carrageenan, sodium ascorbate, ascorbyl palmitate, L-malic acid, L(+)-tartaric acid, maltitol, gelatin, xylitol, citric acid, potassium citrate, sodium citrate, citric acid fatty acid glyceride, agar, lactic acid, sodium lactate, sorbic acid and its potassium salt, sorbitol, acid red, calcium carbonate, sodium carbonate, sodium bicarbonate, beet red, vitamin C, vitamin E, oxidized starch, ethanol, sodium acetate, stearic acid, calcium stearate, magnesium stearate or dextrin.

[0043] Preferably, the pharmaceutically acceptable excipients include, but are not limited to, solvents, diluents, disintegrants, precipitation inhibitors, surfactants, glidants, binders, lubricants, dispersants, suspending agents, isotonic agents, thickeners, emulsifiers, preservatives, stabilizers, hydrating agents, emulsification accelerators, buffers, absorbents, colorants, flavoring agents, sweeteners, ion exchangers, release agents, coating agents, flavoring agents or antioxidants.

[0044] In yet another aspect, the present invention provides a use of the above-mentioned health care product, food or medicine, which comprises administering an effective amount of the health care product, food or medicine to a subject.

[0045] Specifically, the subject is a mammal.

[0046] Preferably, the subject is a human.

[0047] The beneficial effects of the present invention are:

[0048] (1) The Bifidobacterium breve HH079 provided by the present invention has good tolerance to gastric acid and bile salts, and can effectively resist the extreme environment of the upstream digestive tract, thereby smoothly reaching the downstream digestive tract (such as the colon) and exerting healthy functions. This indicates that the Bifidobacterium breve HH079 provided by the present invention can be used for the preparation of probiotic foods, probiotic health products and gastrointestinal tract administration drugs.

[0049] (2) The Bifidobacterium breve HH079 provided by the present invention can improve the structural integrity of intestinal epithelial cells, regulate the levels of pro-inflammatory and anti-inflammatory factors in the body after intestinal flora imbalance, promote macrophage M2 polarization, and regulate intestinal flora, thereby improving the body's immunity.

[0050] Collection Instructions

[0051] Name of biological material: Bifidobacterium breve HH079;

[0052] Category naming: Bifidobacterium breve ;

[0053] Deposit date: December 29, 2023;

[0054] Deposit number: GDMCC No: 64216;

[0055] Depository: Guangdong Microbiological Culture Collection Center;

[0056] Collection address: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 This is the Gram staining image of Bifidobacterium breve HH079.

[0058] Figure 2 Design a protocol flow for the experiment.

[0059] Figure 3 The effect of HH079 supplementation on the growth and development of mice; A is the weight of mice; B is the macroscopic image of the colon; C is the length of the colon; ** in the figure represents p<0.01 compared with the Abx group.

[0060] Figure 4 AB-PAS staining; A is the AB-PAS staining image; B is the goblet cell quantitative data; ** in the figure represents p<0.01 compared with the Abx group; *** represents p<0.001 compared with the Abx group.

[0061] Figure 5 MUC2 immunohistochemistry; Figure A is the immunohistochemical staining; B is the quantitative data of Muc2 protein expression; ** in the figure represents p<0.01 compared with the Abx group

[0062] Figure 6 is the expression level of ZO-1, occludin and CLDN1 proteins; A is the protein immunoblot; B is the gray value analysis; ** in the figure represents p<0.01 compared with the Abx group; * represents p<0.05 compared with the Abx group.

[0063] Figure 7 is the expression level of inflammatory factors; AD in the figure is the expression of serum inflammatory factors determined by ELISA; E is the mRNA expression of inflammatory cytokines; ** in the figure represents p<0.01 compared with the Abx group; * represents p<0.05 compared with the Abx group.

[0064] Figure 8 are the results of macrophage determination; AB in the figure is the number of macrophages determined by flow cytometry; C is the mRNA expression of M1 and M2 macrophage markers; ** in the figure represents p<0.01 compared with the Abx group, and * represents p<0.05 compared with the Abx group.

[0065] Fig. 9 Figure 3 is the effect of Bifidobacterium breve HH079 on the colon transcriptome after antibiotic exposure; A is the PCA analysis; B is the number of up-regulated and down-regulated differentially expressed genes compared with the antibiotic exposure group; C is the volcano plot of differentially expressed genes between the Con group and the Abx group; D is the volcano plot of differentially expressed genes between the HH079 group and the Abx group.

[0066] Fig.10 Is the barrier function gene expression; in the figure, ** represents p<0.01 compared with the Abx group; * represents p<0.05 compared with the Abx group.

[0067] Fig.11 is the expression of macrophage polarization-related genes; A is the expression of M1 macrophage-related genes; B is the expression of M2 macrophage-related genes.

[0068] Fig.12 Pathway enrichment in differentially expressed genes between HH079 group and Abx group.

[0069] Fig.13 TLR4 / NF-κB determination; A in the figure is the WB diagram of TLR4 / NF-κB signaling pathway; B is the expression level of TLR4 / NF-κB signaling pathway; ** in the figure represents p<0.01 compared with the Abx group; * represents p<0.05 compared with the Abx group.

[0070] Fig.14Bifidobacterium breve HH079 regulates the intestinal microbial composition; A in the figure is the α-diversity index; B is the β-diversity evaluated by PCoA analysis, and each figure represents a single sample; C is the relative abundance of intestinal flora at the genus classification level; ** in the figure represents p<0.01 compared with the Abx group; * represents p<0.05 compared with the Abx group. DETAILED DESCRIPTION

[0071] In order to make the technical means, creative features, purpose and efficacy of the present invention easy to understand, the present invention is further explained in conjunction with specific embodiments below, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without creative work all belong to the protection scope of the present invention. In the following embodiments, unless otherwise specified, the operating methods used are conventional operating methods, the equipment used are conventional equipment, and the equipment materials used in each embodiment are the same.

[0072] 1. Experimental reagents

[0073] All experimental reagents of the present invention are shown in Table 1.

[0074] Table 1 Experimental reagents

[0075]

[0076] 2. Experimental Animals

[0077] The present invention uses newborn mice of SPF-grade healthy C57BL / 6J mother mice for experiments.

[0078] 3. Experimental strains

[0079] The strain used in the present invention is Bifidobacterium breve HH079, which is classified and named Bifidobacterium breve , the deposit number is GDMCC No: 64216, and it was deposited in Guangdong Provincial Microbiological Culture Collection Center on December 29, 2023.

[0080] 4. Statistical analysis

[0081] This experiment used the statistical software IBM SPSS 26.0, and the results were expressed as mean ± standard deviation (x ± SD). One-way analysis of variance was used for comparison between groups. p < 0.05 was considered to be significantly different.

[0082] Example 1 Gram staining

[0083] The Gram staining kit was used to perform Gram staining on Bifidobacterium breve HH079 used in the present invention, and the staining steps were as follows:

[0084] (1) Smear: Take the bacteria to be tested and smear them into a thin layer in the center of the slide or add a small amount of sterile water on the slide, mix the bacteria and water evenly, and smear them into a thin layer.

[0085] (2) Drying: After smearing, allow to dry naturally at room temperature, or slightly heat over an alcohol lamp to dry quickly.

[0086] (3) Fixation: Hold one end of the slide with the specimen facing upward and quickly move it back and forth outside the flame of the alcohol lamp 3-5 times, each time for 1 second. The temperature should not be too high to prevent bacterial protein denaturation. Let it cool before staining. It can also be fixed with methanol or ethanol.

[0087] (4) Primary staining: Add crystal violet staining solution and stain for 1-2 minutes, then rinse with clean water to remove the staining solution.

[0088] (5) Mordanting: Add Gram's iodine solution to cover the slide, leave it at room temperature for about 1-2 minutes, and wash with water.

[0089] (6) Decolorization: Add decolorizing solution dropwise and shake for 10-30 seconds until the decolorizing solution no longer appears purple. Immediately rinse off the decolorizing solution with water to terminate the reaction.

[0090] (7) Re-staining: Add red re-staining solution and stain for 30-60 seconds, then wash with water.

[0091] (8) Drying and microscopic examination: Observe under a microscope.

[0092] The above experiments show that the bacteria have a strict anaerobic requirement for oxygen, and the bacteria are gram-positive rods, with rod-shaped or bifurcated rod-shaped cells and no spores. The strain of the present invention is preliminarily determined to be Bifidobacterium breve. Figure 1 The morphological and general characteristics of Bifidobacterium breve HH079 are as follows: it is an anaerobic bacterium and a Gram-positive bacterium; the colonies grown in MRS medium are white solid circles, and the bacterial body is short rod-shaped with bifid branches (Y-shaped or V-shaped) at both ends.

[0093] Example 2 Acid and bile salt resistance test of Bifidobacterium breve HH079

[0094] 1. Preparation of test bacterial suspension

[0095] Bifidobacterium breve HH079 was revived in MRS solid medium and cultured for 48 h. A single colony was picked and cultured in MRS broth and subcultured twice. The concentration was roughly adjusted to 10 8 -10 9 CFU / mL and reserve for use.

[0096] 2. Preparation of simulated gastric acid and bile salt culture medium

[0097] Preparation of simulated gastric acid culture medium: Prepare MRS broth culture medium, and after sterilization, adjust the pH value to 3.0 with 1 mol / L HCL to prepare simulated gastric acid culture medium.

[0098] Preparation of simulated bile salt culture medium: Prepare MRS broth culture medium, add porcine bile salt to a concentration of 0.1% after sterilization, adjust the pH value to 8.0 with 1 mol / L NaOH, and then filter and sterilize with a 0.22 μm microporous filter membrane to prepare bile salt culture medium.

[0099] 3. Gastric acid and bile salt tolerance test

[0100] Acid resistance test of Bifidobacterium breve HH079: 0.9 mL of simulated gastric acid culture solution was dispensed into EP tubes, and 0.1 mL of the prepared bacterial suspension was added, vortexed and mixed, and then placed in an anaerobic incubator at 37 ° C for 2 hours. The tests were conducted at 0 h and 2 h, and 3 parallels were set for the strain at each time point. MRS broth without pH adjustment was used as a control to observe the growth of bacteria and exclude bacterial death caused by other factors.

[0101] Bile salt tolerance test of Bifidobacterium breve HH079: 0.9 mL of bile salt culture solution was dispensed into EP tubes, and then 0.1 mL of the prepared bacterial suspension was added, vortexed and mixed, and then placed in an anaerobic incubator at 37°C for 24 hours. The tests were performed at 0h and 24h, and three parallels were set for the strain at each time point. MRS broth without bile salts was used as a control to observe the growth of bacteria and exclude bacterial death caused by other factors.

[0102] Immediately after the above culture is completed, dilute 10 times in a gradient, select the appropriate dilution and spot on the MRS plate, and culture anaerobically at 37℃ for 24-48 hours for counting. The count result of the 0-hour dilution inoculation is the initial bacterial concentration. The results are compared with the survival rate. The calculation formula is as follows:

[0103] Survival rate (%) = viable bacterial concentration after culture (CFU / mL) / viable bacterial concentration at 0 hours (CFU / mL) × 100%

[0104] The experimental results show that the survival rate of Bifidobacterium breve HH079 after digestion for 2 hours in simulated gastric acid culture medium with pH = 3 is 84.5%; the survival rate after culturing in bile salt culture medium for 24 hours is 84.9%. Therefore, it can be seen that the Bifidobacterium breve HH079 has good tolerance to gastric acid and bile salts, and can effectively resist the extreme environment of the upstream digestive tract, so as to smoothly reach the downstream digestive tract (such as the colon) and play a healthy function. It is worth noting that the Bifidobacterium breve HH079 provided by the present invention is a non-lyophilized bacterial suspension. In this case, Bifidobacterium breve HH079 has good tolerance to gastric acid and bile salts. If it is made into commercial lyophilized bacterial powder, Bifidobacterium breve HH079 has better tolerance to gastric acid and bile salts. Therefore, Bifidobacterium breve HH079 meets the basic requirements as a probiotic.

[0105] Example 3 Experimental Grouping and Administration of Test Samples

[0106] C57BL / 6J mother mice were continuously given drinking water supplemented with antibiotics (ampicillin 1g / L, neomycin sulfate 0.5g / L), and the mice were breastfed after birth until weaning to establish a mouse model of early intestinal dysbiosis. At the same time, the offspring mice that did not drink water with antibiotics were used as the control group (Con, n=8). Starting from 10 days after birth, the antibiotic-exposed mice were randomly divided into two groups, the Bifidobacterium breve HH079 group (HH079, n=10) and the model group (Abx, n=8); the HH079 group mice were given 1×10 9 CFU Bifidobacterium breve HH079 were orally gavaged, and mice in the Abx group were orally gavaged with an equal volume of carrier solution PBS until weaning. At the same time, mice in the control group were orally gavaged with an equal volume of carrier solution PBS until weaning. Eight hours after the last gavage, the mice were fed with CO 2 The mice were humanely euthanized by asphyxiation, and serum and tissues were immediately harvested. The intestinal contents were squeezed into a sterile vial, immediately snap-frozen in liquid nitrogen, and transferred to -80°C for storage. The changes in the intestinal barrier and immune cells in the mouse colon tissue were measured. The experimental design process is shown in Figure 2 .

[0107] Example 4 Effect of Bifidobacterium breve HH079 supplementation on growth and development of mice

[0108] Effects of Bifidobacterium breve HH079 supplementation on body weight and colon length in mice

[0109] After the last intragastric administration of mice in the control (Con) group, model (Abx) group, and Bifidobacterium breve HH079 (HH079) group, the body weights of the mice were measured and recorded. 2 After the mice were humanely euthanized by asphyxiation, the intestinal tissues of the mice were collected and the colon length was measured and recorded.

[0110] The results of the test are as follows Figure 3 As shown in the figure, compared with the control group, antibiotic intervention significantly reduced the body weight and colon length of mice (p<0.05), and the average body weight and colon length of mice after intervention with Bifidobacterium breve HH079 were significantly increased (p<0.05). In summary, early life antibiotic exposure inhibited the growth and development of mice, and Bifidobacterium breve HH079 could reverse these changes. These results indicate that growth retardation caused by early life antibiotic exposure may be related to its disruption of the balance of intestinal microbiota.

[0111] 4.2 AB-PAS staining to detect goblet cell number

[0112] Colon tissue was fixed in 4% buffered paraformaldehyde solution for 48 hours, then embedded in paraffin and dewaxed to water. Alcian blue stain was used for immersion or drip staining for 10 minutes and then washed with water. Oxidation was performed with 0.5% periodic acid aqueous solution for 10 minutes. Rinse with running water for several minutes and then change distilled water twice. Schiff's reagent was used for immersion or drip staining in the dark for 30 minutes. Rinse with running water for 10 minutes. Hematoxylin was used to counterstain the nucleus for about 1 minute, and hydrochloric acid alcohol was used for differentiation, and ammonia water was used to return to blue. Dehydration was performed with 95% alcohol (5 minutes), 95% alcohol (5 minutes), anhydrous ethanol (5 minutes), and anhydrous ethanol (5 minutes). The sections were transparentized with xylene and sealed with neutral gum. The sections were observed under an optical microscope and representative photos were taken to observe the number of goblet cells.

[0113] AB-PAS staining revealed that ( Figure 4 ), compared with the healthy control group, the amount of viscous secretions in the model group was significantly reduced, and the number of goblet cells was significantly reduced. In contrast, after treatment with Bifidobacterium breve HH079, the secretion of mucus protein by colonic epithelial cells increased. This shows that, to a certain extent, Bifidobacterium breve HH079 effectively protects goblet cells in the intestine and stimulates the secretion of viscous protein substances.

[0114] 4.3 Immunohistochemistry

[0115] Colon tissues were fixed in 4% buffered paraformaldehyde solution for 48 hours, embedded in paraffin, and sections were dewaxed into water. Immunofluorescence staining of Muc2 protein in colon tissues was performed.

[0116] Immunohistochemistry results are shown in Figure 5 Compared with the Con group, antibiotic exposure (Abx group) decreased the expression of Muc2 protein. Bifidobacterium breve HH079 promoted the expression of colonic Muc2 protein and protected the integrity of the intestinal mucus barrier.

[0117] 4.4 Immunoblotting

[0118] Immunoblotting experiments were performed on mouse colon tissue for ZO-1, occludin, and CLDN1: 2-3 cm of ileum was cut and ground into powder with liquid nitrogen. The powder was added to the protein loading buffer at a ratio of 1:10 between tissue and buffer, and the solution was boiled for 5 minutes. After cooling to room temperature, the supernatant was taken and added to the prepared 10% protein gel for running. The sample was then transferred to the membrane, blocked with 10% skimmed milk powder for 30 minutes, bound to the primary antibody for 30 minutes, bound to the secondary antibody for 30 minutes, developed with DAB, and photographed and recorded.

[0119] The integrity of the colonic epithelial structure was evaluated by measuring the expression of ZO-1, occludin, and CLDN1 proteins. Compared with the Con group, the Abx group showed lower expression levels of ZO-1, occludin, and CLDN1 genes and proteins, indicating that early-life antibiotic exposure can lead to the destruction of intestinal epithelial cell structural integrity and increase intestinal permeability. However, the relative expression levels of ZO-1, occludin, and CLDN1 in the HH079 group were significantly increased compared with the Abx group (p<0.05). This indicates that probiotic supplementation has a positive effect on intestinal damage caused by early-life antibiotic exposure ( Figure 6 ).

[0120] Example 5 Effect of Bifidobacterium breve HH079 supplementation on inflammatory response in mice

[0121] 5.1 Effects of Bifidobacterium breve HH079 supplementation on inflammatory factors

[0122] 5.1.1 Elisa determination of inflammatory factor levels

[0123] Mouse serum samples were tested for TNF-α, IL-1β, LBP, and IL-10 using ELISA kits according to the instructions provided in the ELISA kits.

[0124] 5.1.2 mRNA determination of inflammatory factor levels

[0125] (1) Use an RNA rapid extraction kit to extract total RNA from the tissue, and reverse transcribe the RNA into cDNA according to the instructions of the cDNA synthesis kit.

[0126] (2) qPCR amplification: RNA reverse transcription reaction was performed using a synthesis kit according to the manufacturer's instructions. The following reaction system was prepared under ice bath conditions: 8 μL RNA template (approximately 0.2 μg total RNA), 15 μL 2×ⅡM-MLVRT Mix, and 7.5 μL RNase-free water. Then, the PCR program parameters were set and the reverse transcription reaction was run: 25°C for 5 min, 42°C for 30 min, and 85°C for 5 min. After the reaction, the concentration of the product cDNA was measured using a Nanodrop ND-2000 spectrophotometer, the OD values ​​at 260 nm and 280 nm were read, and OD260 / OD280 was calculated. If the ratio was between 1.8 and 2.2, it indicated a high purity. At this time, the cDNA stock solution could be diluted and adjusted to a concentration of <150 ng / μL, and stored at -80°C after aliquoting for subsequent experiments.

[0127] (3) Using GAPDH as the internal reference, according to formula 2 −ΔΔCT Calculate the relative mRNA expression of each target gene. Table 2 shows the primer sequences used in this experiment.

[0128] Table 2 Primer sequences

[0129]

[0130] Results Figure 7 , in the Abx group, the secretion expression of proinflammatory cytokines (TNF-α, IL-1β, and IL-6) was significantly increased compared with the control group, while the level of anti-inflammatory cytokine (IL-10) was significantly decreased compared with the control group. In contrast, the levels of TNF-α and LBP in the HH079 group were significantly lower than those in the Abx group. At the mRNA level, compared with the Abx group, the HH079 group significantly downregulated the level of IL-1β and upregulated the level of IL-10. LBP is an acute inflammatory response protein produced by the body when the body is stimulated by lipopolysaccharide, which can cause host inflammatory response and immune disorder. The above results indicate that the supplementation of Bifidobacterium breve HH079 can reduce and increase the levels of proinflammatory and anti-inflammatory cytokines in the body after Abx-induced intestinal flora imbalance. Therefore, the signal transduction pathways and metabolites of Bifidobacterium breve HH079 were studied in depth.

[0131] 5.2 Effects of Bifidobacterium breve HH079 supplementation on macrophages

[0132] 5.2.1 Flow cytometry to measure macrophage count

[0133] To further confirm the effect of B. breve HH079 supplementation on macrophages, the number of macrophages was determined using flow cytometry.

[0134] 5.2.2 Expression of mRNA of M1 and M2 macrophage markers

[0135] The determination of gene expression by qRT-PCR was performed as described in 5.1.2, and the primer sequences are shown in Table 3.

[0136] Table 3 Primer sequences

[0137]

[0138] The results of flow cytometry showed that ( Figure 8 A in Figure 1), where antibiotic treatment significantly affected the balance of macrophages in the colon. In contrast, intervention with Bifidobacterium breve HH079 significantly reduced the number of macrophages. The types of macrophages were further detected by RT-qPCR. CD86 is a co-stimulatory molecule that is often considered to be one of the markers of M1 macrophages (pro-inflammatory macrophages). Figure 8 The BD in the study showed that antibiotic exposure in early life significantly stimulated the expression of the CD86 gene, which means that antibiotics promoted macrophages to be mainly M1 pro-inflammatory macrophages. In contrast, Bifidobacterium breve HH079 promoted the expression of CD206 in colon tissue and significantly inhibited the expression of CD86. HH079 can reverse the polarization of macrophages stimulated by antibiotics from M1 to M2.

[0139] Example 6 Effects of Bifidobacterium breve HH079 on the Colon Transcriptome after Antibiotic Exposure

[0140] 6.1 Transcriptome analysis

[0141] Total RNA was extracted from colon tissue and RNA libraries were constructed. Quantified libraries were analyzed by single-end sequencing on an Illumina genetic analyzer. Data analysis was performed using R software. Raw data of counts and FPKM are available (https: / / bioinfogo.org / ResKsumo / data). Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of differentially expressed genes was performed using the “clusterProfiler” and “GOplot” packages in R software, with standard fold differences less than or equal to 2 and P values ​​less than 0.05.

[0142] 6.2 Western Blot Analysis of TLR4 / NF-κB Signaling Pathway

[0143] Referring to the method described in Section 4.4 of Example 4, an immunoblotting experiment was performed on the TLR4 / NF-κB signaling pathway.

[0144] 6.3 Measurement results

[0145] Based on RNAseq transcriptome analysis, the effect of Bifidobacterium breve HH079 supplementation on antibiotic exposure was studied. As shown in the PCA diagram ( Fig. 9 The volcano plot revealed that antibiotic exposure significantly downregulated 688 genes, while B. breve HH079 supplementation upregulated 605 genes, indicating that B. breve HH079-induced transcriptome changes were not identical to Abx.

[0146] Through KEGG enrichment analysis, compared with genes after antibiotic exposure, supplementation with Bifidobacterium breve HH079 can inhibit the activation of NFkb signaling pathway. Among the significantly related genes, cytokine-cytokine receptor interaction, Th17 chemokine, extracellular matrix receptor interaction and focal adhesion-related signaling pathways were significantly enriched (FDR<0.001). These indicate that early antibiotic exposure can cause tissue cell damage and cause the expression of inflammatory signaling pathways.

[0147] Regarding intestinal epithelial cell proliferation and protective protein peptide secretion genes, Bifidobacterium breve HH079 significantly promoted the upregulation of IgA, Reg3b, Reg3g and Lyz2 genes, among which secretory IgA is the main component of the body's mucosal defense system and the first line of defense against pathogens invading the body. This suggests that early life antibiotic exposure can lead to impaired intestinal epithelial cell integrity and function, and supplementation with Bifidobacterium breve HH079 reversed this situation. Fig.10 .

[0148] The expression of macrophage polarization-related genes is shown in Fig.11 , Abx upregulated multiple M1 macrophage marker genes, such as IL6ra, Nos1, IL1, Cxcl12, etc., while HH079 treatment led to a reversal of the expression of these pro-inflammatory M1 genes. Similarly, HH079 restored the expression of M2 macrophage markers suppressed by early-life antibiotic intervention to normal levels. These findings suggest that B. breve HH079 may promote M1 to M2 polarization in macrophages.

[0149] Combined with transcriptome, it was found that the expression of Toll-NF-κB signaling pathway by Bifidobacterium breve HH079 may be the main signaling pathway regulating inflammatory changes ( Fig.12). The protein expression of Toll-NF-κB signaling pathway after different interventions was determined by WB method. TLR4 is the main receptor of LPS, and TLR4 is significantly expressed in the Abx group. At the same time, the downstream proteins Myd88 and P65 are activated after receiving the signal. However, treatment with Bifidobacterium breve HH079 significantly weakened the expression of Myd88 and P65, indicating that Bifidobacterium breve HH079 can promote the transformation of M1 to M2 by regulating the activation of NF-κB signaling pathway in epithelial tissue cells, and further inhibit the occurrence of inflammation ( Fig.13 ).

[0150] Example 7 Effect of Bifidobacterium breve HH079 on intestinal flora

[0151] Total DNA from mouse fecal samples was extracted using QIAGEN DNA Mini-Kit. DNA was quantified using Nanodrop, and the quality of DNA extraction was evaluated by 0.8% agarose gel electrophoresis. The V3-V4 region of the fecal 16S rRNA gene was amplified by PCR using universal forward primer SEQ ID NO.15 (5′-ACTCCTACGGGAGGCAGCA-3′) and reverse primer SEQ ID NO.16 (5′-GGACTACHVGGGTWTCTAAT-3′), and the amplified product was purified and recovered by magnetic beads. Sequencing libraries were prepared using Illumina's TruSeq Nano DNA LT Library Prep Kit. Sequencing was performed on a MiSeq sequencer. The original high-throughput sequencing data obtained were screened, retested, library and sample partitioned, and chimeras and barcode sequences were removed before denoising and ASV clustering. The composition of each sample at different species taxonomic levels was explored in combination with existing databases. Based on different OUT distributions, the alpha diversity level of the samples and the beta diversity differences between different groups were evaluated to further measure the differences in community structure between different groups.

[0152] The results of the test are as follows Fig.14 As shown, antibiotic treatment significantly reduced the observed species, Chao1, Shannon, and Simpson indices compared with the control group ( Fig.14A in (p<0.05), indicating that early life antibiotic exposure reduced the species richness and evenness of the mouse gut microbiota. In contrast, the addition of B. breve HH079 restored Chao 1, Observed species, Shannon, and Simpson indices by 12.17%, 12.51%, 59.51%, and 92.78%, respectively, relative to the Abx group. Principal coordinate analysis (PCoA) showed that the gut microbiota clusters in the Abx group were more distant from the clusters in the B. breve HH079 group compared with the Con group ( Fig.14 Middle B).

[0153] Next, the composition of the gut microbiota of the three groups was evaluated at the taxonomic level. As shown in Figure C, at the genus level, Parabacteroides and Prevotella The relative abundance of Pseudomonadaceae_ Pseudomonas and Morganella The relative abundance of Morganella A new genotoxin produced may increase the risk of colorectal cancer, Morganella is a type of Enterobacteriaceae, which is considered a sign of intestinal dysbiosis. A shift in the microbiota from Morganella and Pseudomonadaceae_Pseudomonas The dominant community shifted significantly, accompanied by Bifidobacterium, Bacteroides and Proteus In conclusion, the intestinal bacterial community significantly altered by antibiotic exposure may bring about the risk of inflammation, and the enrichment of more bifidobacteria in Bifidobacterium breve HH079 helps to restore the intestinal flora environment.

[0154] The above detailed description is a specific description of one of the feasible embodiments of the present invention, and the embodiment is not intended to limit the scope of the present invention. It should be pointed out that any equivalent implementation or change that does not deviate from the present invention should be included in the scope of the technical solution of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached requirements.

Claims

1. A Bifidobacterium breve ( Bifidobacterium breve ), characterized in that, The Bifidobacterium breve is Bifidobacterium breve HH079, and its preservation number is GDMCC No: 64216.

2. A culture of Bifidobacterium breve HH079, characterized in that: The deposit number of the Bifidobacterium breve HH079 is GDMCC No: 64216.

3. The culture according to claim 2, characterized in that The culture comprises live bacteria of Bifidobacterium breve HH079.

4. The culture according to claim 2, characterized in that The method for preparing the culture comprises: inoculating Bifidobacterium breve HH079 into a culture medium, wherein the culture medium can provide nutrients to Bifidobacterium breve HH079; the nutrients comprise one or more of protein, carbohydrate, fat, probiotics, vitamins, minerals and amino acids.

5. A probiotic composition, characterized in that: The probiotic composition comprises the Bifidobacterium breve according to claim 1 or the culture according to any one of claims 2 to 4.

6. The probiotic composition according to claim 5, characterized in that The probiotic composition also includes nutrients acceptable to food science.

7. The probiotic composition according to claim 6, characterized in that The food-based acceptable nutrients include one or more of dietary fiber, protein, lipids, minerals, and vitamins.

8. Use of the Bifidobacterium breve according to claim 1 or the culture according to any one of claims 2 to 4 in the preparation of a product for enhancing immunity, wherein the product comprises a health product or a medicine.

9. The use according to claim 8, characterized in that: The enhancing of body immunity is enhancing the immunity of mammals.

10. The use according to claim 9, characterized in that: The mammal is a human.

11. The use according to claim 8, characterized in that: The product contains 1×10 6 -1×10 12 CFU / dose of Bifidobacterium breve HH079.

12. A health product comprising the Bifidobacterium breve according to claim 1 or the culture according to any one of claims 2 to 4.

13. The health product according to claim 12, characterized in that: The health care products also include nutritionally acceptable nutrients.

14. The health product according to claim 13, characterized in that: The nutrients include one or more of dietary fiber, protein, lipids, minerals and vitamins.

15. The health care product according to claim 12, characterized in that: The dosage forms of the health care products include tablets, capsules, granules, pills, gel candies, powders, oral liquids or drops.

16. A food comprising the Bifidobacterium breve according to claim 1 or the culture according to any one of claims 2 to 4.

17. The food according to claim 16, characterized in that The dosage form of the food includes liquid dosage form, solid dosage form or semi-solid dosage form.

18. The food according to claim 16, characterized in that The food includes human food or pet food.

19. A medicament comprising the Bifidobacterium breve according to claim 1 or the culture according to any one of claims 2 to 4.

20. The drug according to claim 19, characterized in that The medicine also includes one or more physiologically acceptable excipients.

Citation Information

Patent Citations

  • Bifidobacterium breve 207-1 and application thereof

    CN114317320A

  • Bifidobacterium breve 207-1 and application thereof in regulating lipid metabolism direction

    CN117838737A

  • Bifidobacterium breve CCFM1025, Food Fermented Thereby and Application Thereof

    US20220290095A1

  • Administration of bifidobacterium breve during infancy to prevent inflammation later in life

    WO2011039328A1